This phase III trial is trying to understand how safe and effective combining three types of targeted therapy (pirtobrutinib, venetoclax and rituximab) is, compared to a combination of two targeted therapies (venetoclax and rituximab) in people with chronic lymphocytic leukaemia or small lymphocytic lymphoma that have previously had treatment.
This trial is treating patients with chronic lymphocytic leukaemia and small lymphocytic lymphoma.
This is a systemic therapy trial.
You may be able to join this trial if:
- You are able to swallow medication by mouth.
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322)
Loxo Oncology, Inc.
This is a randomised trial with two arms. In the Experimental Arm, participants will receive fixed duration pirtobrutinib (administered orally), in combination with venetoclax (administered orally) and rituximab (administered intravenously). In the Active Comparator Arm, participants will receive venetoclax (administered orally) and rituximab (administered intravenously).
Recruiting Hospitals Read More